JP5086991B2 - プロスタグランジンｅ２（ｐｇｅ２）の生産に関連する障害の処置のための３−アミノカルバゾールのベンゾイル誘導体の使用 - Google Patents
プロスタグランジンｅ２（ｐｇｅ２）の生産に関連する障害の処置のための３−アミノカルバゾールのベンゾイル誘導体の使用 Download PDFInfo
- Publication number
- JP5086991B2 JP5086991B2 JP2008511591A JP2008511591A JP5086991B2 JP 5086991 B2 JP5086991 B2 JP 5086991B2 JP 2008511591 A JP2008511591 A JP 2008511591A JP 2008511591 A JP2008511591 A JP 2008511591A JP 5086991 B2 JP5086991 B2 JP 5086991B2
- Authority
- JP
- Japan
- Prior art keywords
- production
- aminocarbazole
- group
- pge
- prostaglandin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 17
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 title claims description 8
- 208000035475 disorder Diseases 0.000 title claims description 8
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 15
- 230000004054 inflammatory process Effects 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 9
- 206010037660 Pyrexia Diseases 0.000 claims description 9
- 230000036407 pain Effects 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 206010015150 Erythema Diseases 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- 231100000321 erythema Toxicity 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 229940127293 prostanoid Drugs 0.000 description 14
- 150000003814 prostanoids Chemical class 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 6
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001716 carbazoles Chemical class 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940111134 coxibs Drugs 0.000 description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 230000003040 nociceptive effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000017953 prostanoid receptors Human genes 0.000 description 2
- 108050007059 prostanoid receptors Proteins 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- LRSYZHFYNDZXMU-UHFFFAOYSA-N 9h-carbazol-3-amine Chemical compound C1=CC=C2C3=CC(N)=CC=C3NC2=C1 LRSYZHFYNDZXMU-UHFFFAOYSA-N 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical class C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000633401 Homo sapiens Neuropeptide Y receptor type 5 Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 description 1
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000008013 morphine dependence Diseases 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 230000020964 regulation of blood coagulation Effects 0.000 description 1
- 230000010451 regulation of platelet aggregation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 231100000513 vascular toxicity Toxicity 0.000 description 1
- 230000002666 vasoprotective effect Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2005A000909 | 2005-05-19 | ||
| IT000909A ITMI20050909A1 (it) | 2005-05-19 | 2005-05-19 | Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2- |
| PCT/EP2006/004348 WO2006122680A1 (en) | 2005-05-19 | 2006-05-03 | Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008540591A JP2008540591A (ja) | 2008-11-20 |
| JP2008540591A5 JP2008540591A5 (enExample) | 2009-05-14 |
| JP5086991B2 true JP5086991B2 (ja) | 2012-11-28 |
Family
ID=35219704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511591A Expired - Fee Related JP5086991B2 (ja) | 2005-05-19 | 2006-05-03 | プロスタグランジンｅ２（ｐｇｅ２）の生産に関連する障害の処置のための３−アミノカルバゾールのベンゾイル誘導体の使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8686021B2 (enExample) |
| EP (1) | EP1881826B1 (enExample) |
| JP (1) | JP5086991B2 (enExample) |
| KR (1) | KR101312579B1 (enExample) |
| CN (1) | CN101166528B (enExample) |
| AR (1) | AR054126A1 (enExample) |
| AT (1) | ATE473739T1 (enExample) |
| AU (1) | AU2006246688B2 (enExample) |
| BR (1) | BRPI0609718A2 (enExample) |
| CA (1) | CA2604562C (enExample) |
| DE (1) | DE602006015457D1 (enExample) |
| DK (1) | DK1881826T3 (enExample) |
| EA (1) | EA012724B1 (enExample) |
| ES (1) | ES2347174T3 (enExample) |
| GE (1) | GEP20094738B (enExample) |
| IL (1) | IL186072A (enExample) |
| IT (1) | ITMI20050909A1 (enExample) |
| MX (1) | MX2007013491A (enExample) |
| PL (1) | PL1881826T3 (enExample) |
| PT (1) | PT1881826E (enExample) |
| SI (1) | SI1881826T1 (enExample) |
| UA (1) | UA94044C2 (enExample) |
| WO (1) | WO2006122680A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20051523A1 (it) | 2005-08-03 | 2007-02-04 | Acraf | Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo |
| EP2119705A1 (en) | 2008-05-14 | 2009-11-18 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor |
| US8880004B2 (en) | 2009-05-14 | 2014-11-04 | Qualcomm Incorporated | System and method for resolving conflicts between air interfaces in a wireless communication system |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241368A (ja) * | 1997-02-18 | 2002-08-28 | Shionogi & Co Ltd | 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物 |
| US6399631B1 (en) | 1999-07-23 | 2002-06-04 | Pfizer Inc. | Carbazole neuropeptide Y5 antagonists |
| AU6000900A (en) | 1999-07-23 | 2001-02-13 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| JP2003507424A (ja) * | 1999-08-26 | 2003-02-25 | ブリストル−マイヤーズ スクイブ カンパニー | Ｎｐｙアンタゴニスト：スピロイソキノリノン誘導体 |
| DE10125961A1 (de) | 2001-05-29 | 2002-12-12 | Boehringer Ingelheim Int | Carbazolderivate und deren Verwendung zur Herstellung einer Arzneimittelzusammensetzung zur Behandlung von im Zusammenhang mit NPY stehenden Leiden |
| CA2403307A1 (en) * | 2001-10-23 | 2003-04-23 | Neurogen Corporation | Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives |
| KR20030042344A (ko) * | 2001-11-22 | 2003-05-28 | 한국생명공학연구원 | 에레모필란계 화합물 또는 곰취추출물을 유효성분으로함유하는 염증질환 치료제, 면역질환 치료제, 및 암 치료제 |
| ES2193875B2 (es) * | 2002-04-09 | 2005-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
| KR100402714B1 (ko) * | 2002-12-23 | 2003-11-13 | 한국생명공학연구원 | 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도 |
-
2005
- 2005-05-19 IT IT000909A patent/ITMI20050909A1/it unknown
-
2006
- 2006-05-03 CN CN2006800144162A patent/CN101166528B/zh not_active Expired - Fee Related
- 2006-05-03 PL PL06753538T patent/PL1881826T3/pl unknown
- 2006-05-03 EP EP06753538A patent/EP1881826B1/en not_active Not-in-force
- 2006-05-03 PT PT06753538T patent/PT1881826E/pt unknown
- 2006-05-03 MX MX2007013491A patent/MX2007013491A/es active IP Right Grant
- 2006-05-03 DK DK06753538.5T patent/DK1881826T3/da active
- 2006-05-03 KR KR1020077029661A patent/KR101312579B1/ko not_active Expired - Fee Related
- 2006-05-03 WO PCT/EP2006/004348 patent/WO2006122680A1/en not_active Ceased
- 2006-05-03 JP JP2008511591A patent/JP5086991B2/ja not_active Expired - Fee Related
- 2006-05-03 GE GEAP200610441A patent/GEP20094738B/en unknown
- 2006-05-03 DE DE602006015457T patent/DE602006015457D1/de active Active
- 2006-05-03 BR BRPI0609718-9A patent/BRPI0609718A2/pt not_active IP Right Cessation
- 2006-05-03 AT AT06753538T patent/ATE473739T1/de active
- 2006-05-03 SI SI200630781T patent/SI1881826T1/sl unknown
- 2006-05-03 UA UAA200713598A patent/UA94044C2/ru unknown
- 2006-05-03 AU AU2006246688A patent/AU2006246688B2/en not_active Ceased
- 2006-05-03 EA EA200702534A patent/EA012724B1/ru not_active IP Right Cessation
- 2006-05-03 CA CA2604562A patent/CA2604562C/en not_active Expired - Fee Related
- 2006-05-03 US US11/909,393 patent/US8686021B2/en not_active Expired - Fee Related
- 2006-05-03 ES ES06753538T patent/ES2347174T3/es active Active
- 2006-05-17 AR ARP060101981A patent/AR054126A1/es not_active Application Discontinuation
-
2007
- 2007-09-19 IL IL186072A patent/IL186072A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101166528A (zh) | 2008-04-23 |
| EP1881826A1 (en) | 2008-01-30 |
| IL186072A0 (en) | 2008-08-07 |
| CA2604562C (en) | 2013-09-17 |
| ITMI20050909A1 (it) | 2006-11-20 |
| IL186072A (en) | 2012-05-31 |
| ES2347174T3 (es) | 2010-10-26 |
| PT1881826E (pt) | 2010-08-05 |
| CN101166528B (zh) | 2011-06-15 |
| AU2006246688A1 (en) | 2006-11-23 |
| UA94044C2 (ru) | 2011-04-11 |
| JP2008540591A (ja) | 2008-11-20 |
| KR101312579B1 (ko) | 2013-09-30 |
| KR20080018898A (ko) | 2008-02-28 |
| SI1881826T1 (sl) | 2010-10-29 |
| WO2006122680A1 (en) | 2006-11-23 |
| GEP20094738B (en) | 2009-07-27 |
| MX2007013491A (es) | 2008-01-24 |
| PL1881826T3 (pl) | 2010-12-31 |
| CA2604562A1 (en) | 2006-11-23 |
| AR054126A1 (es) | 2007-06-06 |
| US20080287518A1 (en) | 2008-11-20 |
| BRPI0609718A2 (pt) | 2011-10-18 |
| EP1881826B1 (en) | 2010-07-14 |
| EA012724B1 (ru) | 2009-12-30 |
| DE602006015457D1 (de) | 2010-08-26 |
| HK1119571A1 (en) | 2009-03-13 |
| ATE473739T1 (de) | 2010-07-15 |
| EA200702534A1 (ru) | 2008-04-28 |
| AU2006246688B2 (en) | 2011-09-22 |
| US8686021B2 (en) | 2014-04-01 |
| DK1881826T3 (da) | 2010-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5922116B2 (ja) | 複数のプロスタグランジン受容体で作用する全般的な抗炎症反応をもたらす化合物 | |
| CN103249408A (zh) | 利用多不饱和长链酮类的类风湿性关节炎治疗 | |
| JP2017114861A (ja) | モノアミン神経伝達物質によって影響を受ける病態の処置における（＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］ヘキサンの調製および使用 | |
| KR20060096145A (ko) | 티헬퍼세포-2에서 발현되는 유사수용체 유도성 물질의길항제 화합물의 치료용도 | |
| KR101333753B1 (ko) | 세포 손상 및 염증 질환의 치료 또는 예방용 약학 조성물 | |
| KR101278620B1 (ko) | 3-아미노카바졸 화합물, 이를 함유하는 약학적 조성물 및이의 제조 방법 | |
| La Corte et al. | Prophylaxis and treatment of NSAID-induced gastroduodenal disorders | |
| JP5086991B2 (ja) | プロスタグランジンｅ２（ｐｇｅ２）の生産に関連する障害の処置のための３−アミノカルバゾールのベンゾイル誘導体の使用 | |
| US4694018A (en) | Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives | |
| WO2006016689A1 (ja) | Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤 | |
| KR101189751B1 (ko) | 세포 손상 및 염증 질환의 치료 또는 예방용 약학 조성물 | |
| FI107609B (fi) | Menetelmä terapeuttisesti käyttökelpoisten 3-(1-substituoituja pyratsoyyli)-2-oksi-indolijohdannaisten valmistamiseksi | |
| JPH0633258B2 (ja) | ２―グアニジノ―４―アリールチアゾール化合物 | |
| WO2004089411A1 (ja) | 脊柱管狭窄症治療剤 | |
| Romeiro et al. | Synthesis, pharmacological evaluation and docking studies of new sulindac analogues | |
| HK1119571B (en) | Use of a benzoyl derivative of 3-aminocarbazole in manufacture of a medicament in the treatment of a disorder associated with the production of prostaglandin e2 (pge2) | |
| JPH06509110A (ja) | 胃及び十二指腸障害を治療する方法及び組成物並びに新規なｐｇｅ↓２誘導体 | |
| TWI325317B (en) | Appetite-stimulating agents and remedies for anorexia | |
| MODEL | PHARMACEUTICAL SCIENCES | |
| Pepper | NONSTEROIDAL ANTIINFLAMMATORY DRUGS: New Perspectives on a Familiar Drug Class | |
| RU2643669C1 (ru) | 3-[3-(морфолин-4-ил)пропил]-2-[(2,2,3-триметилциклопент-3-ен-1-ил)метил]-1,3-тиазолидин-4-он, обладающий противоязвенной и противовоспалительной активностью | |
| TW379220B (en) | Pyrazolidine derivative, radical scavenger, brain--infarction depressant, and brain-edma depressant | |
| Chetty Raju et al. | Cyclooxygenase inhibitors | |
| TW200530219A (en) | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds | |
| TW201306838A (zh) | 菸鹼酸模擬物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090323 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090323 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120424 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120723 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120828 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120907 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150914 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |